Ascendis Pharma Investor Relations Material

Ascendis Pharma A/S is a biopharmaceutical company leveraging its TransCon technology platform to develop treatments for patients with unmet medical needs in endocrinology and oncology. The company's proprietary TransCon technology is designed to enhance the efficacy, safety, and administration of existing molecules, resulting in new therapies that could potentially offer best-in-class benefits. Ascendis Pharma's approach combines the benefits of prodrug and sustained-release technologies, enabling the controlled release of active pharmaceutical ingredients. The company is headquartered in Copenhagen, Denmark, and its shares are listed on the NASDAQ under the ticker symbol ASND.